Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus bought 575,946 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $9.64 per share, for a total transaction of $5,552,119.44. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.08 on Tuesday, hitting $9.73. The stock had a trading volume of 888,000 shares, compared to its average volume of 804,741. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals, Inc. has a 12-month low of $8.07 and a 12-month high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The firm had revenue of $26.94 million during the quarter, compared to analyst estimates of $27.97 million. During the same quarter in the previous year, the firm earned ($0.35) EPS. Lexicon Pharmaceuticals’s quarterly revenue was down 2.8% compared to the same quarter last year. sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/14/lexicon-pharmaceuticals-inc-lxrx-director-public-equities-l-p-invus-buys-575946-shares.html.

A number of large investors have recently modified their holdings of LXRX. Cubist Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $149,000. Parametric Portfolio Associates LLC purchased a new position in Lexicon Pharmaceuticals in the 2nd quarter worth about $182,000. C WorldWide Group Holding A S raised its position in Lexicon Pharmaceuticals by 49.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 5,353 shares during the last quarter. First Mercantile Trust Co. raised its position in Lexicon Pharmaceuticals by 11.2% in the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 1,227 shares during the last quarter. Finally, Cim Investment Mangement Inc. purchased a new position in Lexicon Pharmaceuticals in the 2nd quarter worth about $262,000.

LXRX has been the subject of several recent analyst reports. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. BidaskClub lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Wedbush reaffirmed an “ourperform” rating and issued a $39.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $28.75.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.